Study summary · research use only
[Genomic instability in atherosclerosis]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this comparative study, the authors examined genomic instability and quantitative and structural chromosome mutations in lymphocyte cultures from patients with atherosclerosis aged 80 years and older, versus a younger control group. The abstract also assessed correction of disturbed genomic indicators by the peptide bioregulator Livagen (Lys-Glu-Asp-Ala) and cobalt ions, alone or combined. It reports that atherosclerosis patients showed a high level of genomic instability across all parameters regardless of age, suggesting increased chromatin condensation, and that Livagen alone and with cobalt ions promoted normalization of altered genomic indicators in both age groups. The authors describe an identified protective action of Livagen in atherosclerosis prevention.
Abstract
A comparative study of the level of genomic instability, parameters of quantitative and structural mutations of chromosomes (aberration, aneuploidy, polyploidy) in lymphocyte cultures from patients with atherosclerosis of age 80 years and older (control group - 30-35 years old) was conducted. The possibility of correction of disturbed genomic indicators by peptide bioregulators - Livagen (Lys-Glu-Asp-Ala) and cobalt ions with separate application or in combination was also studied. Control was lymphocyte culture of two healthy respective age groups. It was also shown that patients with atherosclerosis exhibit high level of genomic instability in all studied parameters, regardless of age, which may suggest that there is marked increase in chromatin condensation in atherosclerosis. It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups. The results show that Livagen separately and in combination with cobalt ions has impact on chromatin of patients with atherosclerosis. The identified protective action of Livagen proves its efficacy in prevention of atherosclerosis.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.